Skip to main content
Premium Trial:

Request an Annual Quote

Drug of Choice

The Wall Street Journal reports that GlaxoSmithKline is seeking direction from healthcare officials in France, Italy, Spain, and the UK on what drugs under development at Glaxo should be pursued. The pharma company hopes that this will give rise to more drugs that the healthcare systems will buy. A blog post from the WSJ highlights this problem: UK health advisors decided that Glaxo's new breast cancer drug, Tyverb (Tykerb in the US), isn't effective enough for to warrant its £20,000 per year price tag.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.